KMDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kamada Ltd (KMDA) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company demonstrates strong financial growth, positive analyst sentiment, and a refocused strategy on core products. Despite a recent price decline, the technical indicators suggest a neutral to slightly bullish trend, and there are no significant negative catalysts.
The MACD is positive but contracting, indicating a neutral to slightly bullish trend. RSI is neutral at 52.959, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 8.491, and resistance is at 9.24. The stock is trading close to its pivot point of 8.865, suggesting limited downside risk.
Financial performance in Q3 2025 shows strong growth: Revenue up 12.63% YoY, Net Income up 37.10% YoY, and EPS up 28.57% YoY.
Analyst upgrade with a price target increase to $13, citing a refocus on core products.
Bullish moving averages and positive MACD.
Recent price decline of -4.30% in the regular market and -3.54% pre-market.
No recent news or significant trading trends from hedge funds, insiders, or congress.
In Q3 2025, Kamada Ltd reported a 12.63% YoY increase in revenue to $47,010,000, a 37.10% YoY increase in net income to $5,296,000, and a 28.57% YoY increase in EPS to 0.09. Gross margin also improved by 1.82% YoY to 42.04%.
H.C. Wainwright raised the price target to $13 from $11 and maintained a Buy rating, citing the company's decision to discontinue a non-core clinical trial and refocus on core products. This eliminates a long-standing distraction and is viewed positively by analysts.
